TGF-β and colorectal carcinogenesis

Microscopy Research and Technique

Volumn 52, Issue 4, 2001, Pages 450-457

  Roman, Christopher ^a   Saha, Debabrata ^a   Beauchamp, R Daniel ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenoma; Carcinogenesis; Colorectal; Smad; TGF

Indexed keywords

PATHOLOGY; SIGNAL TRANSDUCTION;

ADENOMA; CARCINOGENESES; COLORECTAL; COLORECTAL CARCINOGENESIS; HUMAN CANCER; SIGNAL TRANSDUCTION PATHWAYS; SMAD; TGF-Β; TUMOUR CELLS; TUMOUR SUPPRESSOR;

TUMORS;

CYCLOOXYGENASE 2; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL SURVIVAL; COLON CARCINOGENESIS; COLORECTAL CANCER; ENZYME REGULATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

RODENTIA;

EID: 0035865413     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O     Document Type: Review

References (87)

1. Arai T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y. 1998. Genomic structure of the human smad3 and its infrequent alteration in colorectal cancers. Cancer Lett 122:157-163.
2. Arteaga CL, Tandon AK, DD, VH, Osborne CK. 1988. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48:3898-3904.
3. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. 1993. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4:193-201.
4. Atfi A, Buisine M, Mazars A, Gespach C. 1997a. Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-b through stress-activated protein kinase/c-Jun N-terminal Kin(SAPK/JNK) signaling pathway. J Biol Chem 272:24731-24734.
5. Atfi A, Djelloul S, Chastre E, Davis RR, Gespach C. 1997b. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/ c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J Biol Chem 272:1429-1432.
6. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL. 1989. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci USA 86:1578-1582.
7. Barnard JA, Warwick GJ, Gold LL 1993. Localization of transforming growth factor beta isoforms in the normal murine small intestine and colon. Gastroenterology 105:67-73.
8. Beauchamp RD, Peeler MO, DuBois RN. 1996. Recent advances in the management of colorectal polyps. Curr Opin Gastroenterol 12:12-17.
9. Birchenall-Roberts MC, Ruscetti FW, Kasper J, Lee HD, Friedman R, Geiser A, Sporn MB, Roberts AB, Kim SJ. 1990. Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex. Mol Cell Biol 10:4978-4983.
10. Brown JD, DiChiarra MR, Anderson KR, Gimbrone MA Jr, Topper JN. 1999. MEKK-1, a component of the stress (Stress-activated protein Kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J Biol Chem 274:8797-8805.
11. Caulin C, Scholl FG, Frontelo P, Gamallo C, Quintanilla M. 1995. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-β1 induces an epithelial-mesenchymal transdifferentiation and spindle tumoral phenotype. Cell Growth Differ 6:1027-1035.
12. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. 1996. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-542.
13. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH. 1987. Synthesis of messenger RNA for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712.
14. Dumont N. 1999. Genetic and epigenetic contributions to colorectal cancers. APMIS 107:711-722.
15. Engel ME, Datta PK, Moses HL. 1998. RhoB is stabilized by Transforming Growth Factor β and antagonizes transcriptional activation. J Biol Chem 273:9921-9926.
16. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. 1996. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552.
17. Eshelman JR, Markowitz SD. 1995. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 7:83-89.
18. Fearon ER. 1994. Molecular genetic studies of the adenoma to carcinoma sequence. Adv Int Med 39:123-147.
19. Filmus J, Zhao J, Buick RN. 1992. Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones. Oncogene 7(3):521-526.
20. Frey RS, Mulder KM. 1997. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase Jun N-terminas kinase activation by transforming growth factor β in the negative control of breast cancer cells. Cancer Res 57:628-633.
21. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. 1995. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4:549-554.
22. Geiser AG, Kim S, Roberts AB, Sporn MB. 1991. Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol 11:84-92.
23. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, Markowitz S. 1998. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58:3101-3104.
24. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim S-J, Kinzler KW, Vogelstein B, Willson JKV, Markowitz S. 1999. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 59:320-324.
25. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. 2000. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Eng J Med 342(2):69-77.
26. Hafez MM, Hsu S, Yan Z, Winawer S, Friedman E. 1992. Two roles for TGF-β1 in colon enterocytic differentiation. Cell Growth Differ 3:753-762.
27. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. 1996. DPC4, A candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
28. mapk in proliferating cultures of epithelial cells. J Biol Chem 270:7117-7124.
29. Hata A, Shi Y, Massague J. 1998. Tgf-β signaling and cancer: structural and functional consequences of mutations in Smads. 4:257-262.
30. Hocevar BA, Brown TL, Howe PH. 1999. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 18:1345-1356.
31. Hoosein NM, Mcknight MK, Levine AE, Mulder KM, Childress KE, Brattain DE, Brattain MG. 1989. Differential sensitivity in subclasses of human colon carcinoma cell lines to the growth inhitory effects of transforming growth factor-β1. Exp Cell Res 181:442-453.
32. Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P. 1998. Mutations in the Smad4/DPC4 gene in juvenile polyposis. Science 280:1086-1088.
33. Jass JR. 1999. Towards a molecular classification of colorectal cancer. Int J Colorect Dis 14(4-5):194-200.
34. Keeton MR, Curriden SA, Van Zonneveld A-J, Loskutoff DJ. 1991. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β. J Biol Chem 266:23048-23052.
35. Kimchi A, Wang XF, Weinberg RA, Cheifetz S, Massague J. 1988. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science 240:196-199.
36. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
37. Ko TC, Sheng HM, Reisman D, Thompson EA, Beauchamp RD. 1995. Transforming growth-factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene 10(1):177-184.
38. Ko TC, Yu W, Sakai T, Sheng H, Shao J, Beauchamp RD, Thompson EA. 1998. TGF-β effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene 16: 3445-3454.
39. Kurokowa M, Lynch K, Podolsky DK. 1987. Effects of growth factors on an intestinal epithelial cell line: transforming growth factor beta inhibits proliferation and stimulates differentiation. Biochem Biophys Res Commun 142:775-782.
40. Lu SL, Akiyama Y, Nagasaki H, Saitoh K, Yuasa Y. 1995. Mutations of the transforming growth factor-β type II gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun 216:452-457.
41. MacGrogan D, Pergram M, Slamon D, Bookstein R. 1997. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15:1111-1114.
42. Manning AM, Williams AC, Game SM, Paraskeva C. 1991. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 6:1471-1476.
43. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler K, Vogelstein B, Brattain M, Willson JKV. 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with mircrosatellite instability. Science 268:1336-1338.
44. Massague J. 1998. TGF-β Signal Transduction. Annu Rev Biochem 67:753-791.
45. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, Utsunomiya J, Kuroki T, Mori T. 1999. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18:3098-3103.
46. Miettinen PJ, Ebner R, Lopez AR, Derynck R. 1994. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 127:2021-2036.
47. Moustakas A, Stournaras C. 1999. Regulation of actin organisation by TGF-β in H-ras-transformed fibroblasts. J Cell Sci 112:1169-1179.
48. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. 1996. TGF-betal and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10:2462-2477.
49. Oft M, Heider K-H, Beug H. 1998. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243-1252.
50. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. 1995. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550.
51. Podolsky DK. 1997. Healing the epithelium: solving the problem from two sides. J Gastroenterol 32:122-126.
52. Prunier C, Mazars A, Noe V, Bruyneel E, Mareel M, Gespach C, Atfi A. 1999. Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion. J Biol Chem 274:22919-22922.
53. Raftery LA, Twombly V, Wharton K, Gelbart WM. 1995. Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Genetics 139:241-254.
54. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR. 1996. Mad related genes in the human. Nat Genet 13:347-349.
55. Robson H, Anderson E, James RD, Schofield PF. 1996. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74:753-758.
56. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, mackawa T, Ishii S. 1999. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J Biol Chem 274:8949-8957.
57. Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, Padgett RW. 1996. Caenorhbditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci USA 93:790-794.
58. Schroy P, Rikfin J, Coffey RJ, Winawer S, Friedman E. 1990. Role of TGFβ1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. Cancer Res 50:261-265.
59. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. 1995. Genetic characterization and cloning of Mothers against DPP, a gene required for decapentaplegic function in drosophila melanogaster. Genetics 139:1347-1358.
60. Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PCHBD, DuBois RN, Beauchamp RD. 1999. Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene 18:855-867.
61. Sheng H, Shao J, Dixon D, Williams C, Prescott S, DuBois RN, Beauchamp RD. 2000. TGF-β1 Enhances Ha-Ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA. J Biol Chem 275(9):6628-6635.
62. Shibuya H, Kyoko Y, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N, Irie K, Nishida E, Matsumoto K. 1996. TAB1: An activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272:1179-1182.
63. Sieweke MH, Bissell MJ. 1994. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncogen 5:297-311.
64. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. 1990. Mediation of wound-related Rous-sarcoma virus tumorigenesis by TGF-β. Science 248:1656-1660.
65. Smith RG. 1994. Southwestern internal medicine conference: hereditary predisposition to colorectal cancer: new insights. Am J Med Sci 308:295-308.
66. Sun L-Z, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wange J, Gentry LE, Wang X-F, Brattain MG. 1994. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269:26449-26455.
67. Takagi Y, Kohmura H, Futamura M, Kida H, Tanemura H, Shimokawa K, Saji S. 1996. Somatic alterations of the DPC4 gene in human colorectal cancers in Vivo. Gastroenterology 111:1369-1372.
68. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. 1998. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92:645-656.
69. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. 1996. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:343-346.
70. Thibodeau SN, Bren G, Schaid D. 1993. Microsatellite instability in cancer of the proximal colon. Science 260:816-819.
71. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490.
72. Townsend CM Jr, Beauchamp RD. 1995. New developments in colorectal cancer. Curr Opin Gastroenterol 11:36-42.
73. Tsujii M, DuBois R. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
74. Tsujii M, Kawano S, Nagano K, Tsujii S, Sawaoka H, DuBois RN. 1997a. Induction of vascular endothelial tubular morphogenesis by Caco-2 cells programmed to overexpress cyclooxygenase-2. Gastroenterology A3610.
75. Tsujii M, Kawano S, DuBois RN. 1997b. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340.
76. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.
77. Van Aelst L, D'Souza-Schorey C. 1997. Rho GTPases and signaling networks. Genes Dev 11:2295-2322.
78. Wang J, Sun L-Z, Myeroff L, Wang X-f, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK, Brattain MG. 1995. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270: 22044-22049.
79. Winesett MP, Ramsey GW, Barnard JA. 1996. Type II TGF(beta) receptor expression in intestinal cell lines and in the intestinal tract. Carcinogenesis 17:989-995.
80. Woo PL, Cha HH, Singer KL, Firestone GL. 1996. Antagonistic regulation of tight junction dynamics by glucocorticoids and transforming growth factor-β in mouse mammary epithelial cells. J Biol Chem 271:404-412.
81. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270:2008-2011.
82. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N, Nishida E, Shibuya H, Matsumoto K. 1999. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J 18:179-187.
83. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JKV. 1999. Contextual Effects of Transforming Growth Factor β on the Tumorigenicity of Human Colon Carcinoma Cells. Cancer Res 59:4725-4731.
84. Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiori A, Giannetti A, De Luca M. 1995. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol 129:853-865.
85. Zhang X, Wang T, Batist G, Tsao MS. 1994. Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells. Cancer Research 54:6122-6128.
86. Zhang T, Nanney LB, Peeler MO, Williams CS, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD. 1997. Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res 57:1638-1643.
87. Zhu Y, Richardson JA, Parada LF, Graff JM. 1998. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703-714.